 Dan Weirda, Ph.D. |
Dan is an immunotoxicologist with more than 30 years of experience in academia and the industry with expertise in the areas of immunotoxicity, immunogenicity and biopharmaceutical preclinical drug development. He was a research fellow at Eli Lilly and Company until he retired in 2010.
As an independent toxicology consultant, he can provide expertise in conducting preclinical pharmacology and GLP toxicology studies for biologics and small-molecule drugs. He also has in-depth experience in the technical conduct of GLP immunogenicity and immunotoxicity studies and in developing immunogenicity risk-mitigation strategies for biopharmaceuticals. |